Methotrexate treatment in rheumatoid arthritis: Management in clinical remission, common infection and tuberculosis. Results from a systematic literature review

Clinical Rheumatology

Volumn 29, Issue 6, 2010, Pages 629-635

  Bogas, Mónica ^a   Machado, Pedro ^b   Mourão, Ana Filipa ^c   Costa, Lúcia ^a   Santos, Maria José ^d   Fonseca, João Eurico ^e,f   Silva, José António P ^b   Canhão, Helena ^e,f  

^a Unidade Local de Saude do Alto Minho   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c HOSPITAL EGAS MONIZ   (Portugal)

^d HOSPITAL GARCIA DE ORTA   (Portugal)

^e HOSPITAL DE SANTA MARIA   (Portugal)

^f UNIVERSITY OF LISBON   (Portugal)

Author keywords

Infection; Methotrexate; Remission; Rheumatoid arthritis; Systematic literature review; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; CHLOROQUINE; METHOTREXATE; PREDNISONE;

ARTICLE; BRONCHITIS; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG USE; EVIDENCE BASED MEDICINE; EXPERIENCE; HERPES ZOSTER; HUMAN; INFECTION; INFLUENZA; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; MYCOSIS; PNEUMOCYSTIS CARINII; POPULATION; PORTUGAL; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCREENING; SINUSITIS; SKIN INFECTION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS HEPATITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EVIDENCE-BASED MEDICINE; HUMANS; INFECTION; METHOTREXATE; TUBERCULOSIS;

EID: 77954425026     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1380-z     Document Type: Article

References (28)

1. Aletaha D, Smolen JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1, 300 consecutive DMARD courses. Rheumatology 41:1367-1374
2. Borchers AT, Keen CL, Cheema GS, Gershwin ME (2004) The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum 34:465-483
3. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS (2003) Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21:179-185
4. Visser K, Katchamart W, Loza E, Martinez-Lopez JA et al (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086-1093
5. Saleem B, Nizam S, Emery P (2006) Can remission be maintained with or without further drug therapy in rheumatoid arthritis? Clin Exp Rheumatol 24:37-40
6. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS (2007) Assessing remission in clinical practice. Rheumatology 46:975-979
7. Koivuniemi R, Leirisalo-Repo M, Suomalainen R, Piirainen H, Paimela L (2006) Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol 35:273-276
8. Naz SM, Symmons DP (2007) Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 21:871-883
9. Blöndal K (2007) Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis. Bull World Health Organ 85:387-390
10. WHO Report (2008) www.who.int/tb/publications/global-report/2008/pdf/ annex-3.pdf
11. Vadillo Font C, Hernández-García C, Pato E et al (2003) Incidencia y características de la tuberculosis en pacientes con enfermedades reumáticas autoinmunes. Rev Clin Esp 203:178-182
12. Carmona L, Hernández-García C, Vadillo C et al (2003) EMECAR Study. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30:1436-1439
13. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, BIOBADASER GROUP (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122-2127
14. van Tulder M, Furlan A, Bombardier C, Bouter L (2003) Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 28:1290-1299
15. Guyatt G, Rennie D, Hayward R et al (2007) Users' guides to the medical literature: a manual for evidence-based clinical practice. In JAMA: http://pubs.ama-assn.org/misc/usersguides.dtl
16. Phillips B, Ball C, Sackett D et al (2001) Oxford centre for evidence-based medicine levels of evidence. In EBM tools: http://www.cebm.net/ index.aspx?o=1025
17. Luis M, Pacheco-Tena C, Cazarín-Barrientos J et al (1999) Comparision of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study. Arthritis Rheum 42:2160-2165
18. van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW (1994) Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 53:224-228
19. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA (1990) Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol 17:1628-1635
20. Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL (1996) Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int 15:195-200
21. Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum 54:628-634
22. Antonelli MA, Moreland LW, Brick JE (1991) Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 90:295-298
23. Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS (2000) Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 18:363-368
24. Nissen MJ, Fontanges E, Allam Y, Zoulim F, Trépo C, Miossec P (2005) Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology 44:1016-1020
25. Kujawska A, Clements M, Wise CM, Roberts WN (2003) Hepatitis C and methotrexate. Arthritis Rheum 15:843-845
26. Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M (2006) Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 16:282-288
27. Perhala RS, Wilke WS, Clough JD, Segal AM (1991) Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 34:146-152
28. Jain A, Witbreuk M, Ball C, Nanchahal J (2002) Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg [Am] 27:449-455